Cohance Lifesciences Limited — Updates, 26-08-2026: General Updates

Cohance Lifesciences completed its merger, expanding its CRDMO platform. This year, revenue hit ₹2,269 Cr, Adjusted EBITDA ₹477 Cr, and net cash ₹153 Cr. Expect continued growth from new commercial orders, especially in ADC/Oligo. Nacharam facility received a US FDA Warning Letter; minor filing delay also noted.